The global needle-free injection system market size is anticipated to grow with a CAGR of 16.3% from 2023 to 2028 and will be worth USD 26.95 Billion by 2028 from USD 18.51 billion in 2023.
Needle-Free injections are tools used without scratching the skin with a traditional needle to deliver fluid medications, medicines, and vaccines. Since these systems enhance the immune response to vaccines, minimize needle threats, and raise healthcare costs, increasing demand has been seen in these systems' demands. Needle-free techniques deliver a very apparent advantage in patients to minimize needle phobia. In the past few years, the number of patients utilizing self-administered drugs has increased significantly. Also, the Disease Control and Prevention Centers and Division of Diabetes Translation (DDT) support state and local health agencies in promoting initiatives and programs aimed at reducing or preventing diabetes mellitus and improving the health outcomes of patients with diabetes.
Rising chronic disease prevalence, increased incidence of contagious disease due to needle stick injuries, increased demand for biosimilars and immunization, benefits of drug delivery technology, and increased demand for self-injection devices are key factors driving the global needle-free injection system market growth. For example, the disposable Syringe Jet Injector Project favors clinical research studies using jet injectors to supply vaccines. As a result, the rising demand for biosimilars and vaccination will increase the need for this device.
It is possible to configure needle-free injectors as needed and they can be adjusted to maximize their productivity. Nevertheless, it may be challenging to implement a Needle-Free injection system. Also, high training costs and high needle-free injector production costs over traditional needle injection could hamper the global needle-free injection system market growth in the years ahead.
The needle-free injection technique removes the risks of skin puncture or bleeding and swelling issues. Associations such as WHO and CDC, the Centre for Disease Control, and organizations such as the Gates Foundation serve the needs of needle-free drug delivery options that will create enormous future growth opportunities.
Impact of COVID-19 on the global needle-free injection system market:
The coronavirus outbreak (COVID-19) has affected millions of people keeping lives at risk and every business sector, including healthcare. The eruption has spread to almost every corner of the world. The various governments had imposed the lockdowns following strict guidelines to avoid spreading the virus. Patients have stopped visiting the clinics and hospitals during the lockdown, and all the doors remained temporarily closed during the pandemic. The outbreak has impacted the needle-free injection system and continues to do the same. The creative maker of needle-free injections PharmaJet, disclosed its Stratis Needle-free injection used for delivering vaccines against COVID-19 in clinical trials in Australia. COVIDIEN is a DNA-based vaccine advanced by French-Thai Pharma Company BioNet and Melbourne-based biotech Technovalia. The phase 1 trial is a collaboration. The PharmaJet's needle-free injection delivers messenger RNA (mRNA) vaccine in opposition to SARA-CoV-2. Abnova Corporation enhanced the vaccine comprising of new adjuvant increasing the efficiency of the mRNA patient. Abnova Corporation is the world's most significant antibody producer in Taiwan, China.
Market Size Available
2022 to 2028
2023 to 2028
By Product, Source of Power, Usability, Type, Site of Delivery, Application, End User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global needle-free injection system market has been segmented and sub-segmented based on the product, power source, usability, type, delivery site, application, end-user, and region.
Needle-Free Injection System Market - By Product:
Based on the product, the prefilled needle-free injection system segment is projected to grow at a significant CAGR during the forecast period. The acceleration in the incidence rate of chronic diseases such as diabetes needs an appropriate portion to be controlled by the patient is one of the factors primarily driving the growth of this segment.
Simultaneously, the fillable product segment will perform well during the forecast timeline.
Needle-Free Injection System Market - By Source of Power:
Based on the power source, the air-forced injector systems segment is expected to lead the market, accounting for the highest market share during the forecast period. Benefits associated with the air-forced-injected systems, such as quick drug delivery and better replicability resulting in improved availability, are majorly propelling the growth of this segment.
Needle-Free Injection System Market - By Type:
Based on type, the liquid-based needle-free injection system is anticipated to grow fastest during the forecast period. The burgeoning demand for biologics and advanced technologies accentuates the market growth. As a result, the liquid-based type segment is another lucrative segment.
Needle-Free Injection System Market - By Usability:
Based on usability, the reusable usability segment is forecasted to witness healthy growth during the forecast period.
Needle-Free Injection System Market - By Site of Delivery:
Based on the delivery site, the subcutaneous injectors segment is projected to dominate the market due to the growing importance of patients towards the self-administration of drugs.
Needle-Free Injection System Market - By Application:
Based on application, Insulin delivery is the most prominent application segment in the needle-free drug delivery device market. Growth in this segment appears to be an increase in the incidence of diabetes and a shift to an unhealthy lifestyle. For example, according to the Centers for Disease Control and Prevention, about 30.3 million people worldwide had diabetes in 2017, of which 9.4% were U.S. citizens. However, approximately 23.1 million have been diagnosed, and 7.2 million have not.
With the introduction of technologically advanced products such as micro insulin pumps, insulin pens, insulin sprays, respirable insulin, and other new jet injectors, the field of insulin delivery is expected to achieve significant CAGR within the forecast period.
Needle-Free Injection System Market - By End User:
Based on the end-user, the hospitals and clinics segment is expected to be the leading segment during the forecast period. With an escalating patient count and an increasing number of older people, the rising number of chronic diseases will likely propel the market growth. Moreover, the medicine development and advancements in drug delivery, expanding healthcare expenses, and sound knowledge on health and wellness, upsurge the market growth.
Needle-Free Injection System Market - By Region
In the last few years, North America has dominated the global needle-free injection system market, with a significant share held by the United States. Nevertheless, Europe is expected to grow at the highest CAGR in the forecast period. The robust growth in this market is due to the increasing demand for biologics, the rising prevalence of chronic conditions, technological advances, mergers and acquisitions by major market players, favorable reimbursement policies, increased healthcare spending, and authorizations of the new injection system are key factors driving the growth of the European Needle Free Injection System Market.
Asia-Pacific offers lucrative business opportunities to grow due to the high population base and increased awareness of the advantages of Needle-Free injections and their use in cancer and diabetes care. However, Japan is projected to see the fastest growth throughout the forecast period due to patients ' propensity towards advanced technology, increased demand for biologics, and increased healthcare spending.
KEY MARKET PLAYERS:
Some of the significant participants dominating the global needle-free injection system market profiled in this report are Akra Dermojet, Antares Pharma, Becton Dickinson and Company, Bioject Medical Technologies, Crossject, Endo International, European Pharma Group, Glide Pharma Technologies, INJEX Pharma, Inovio Pharmaceuticals, Lundbeck, Medical International Technology, MedImmune, Mystic Pharmaceuticals, National Medical Products, Optinose, PenJet Corporation, PharmaJet, Powderject Pharmaceuticals, PowderMed, Valeritas, Weston medical and Zogenix
RECENT MARKET HAPPENINGS:
The global needle-free injection system market was valued at USD 15.92 billion in 2022.
The growing prevalence of needlestick injuries, growing demand for self-administration of drugs, rising healthcare expenditure, and technological advancements in needle-free injection systems majorly drive the growth of the needle-free infection system market.
The Needle-Free Injection System Market is driven by regions such as North America, Europe, and Asia Pacific, due to increasing healthcare expenditure, rising demand for advanced healthcare products, and growing awareness about the benefits of needle-free injection systems.
The key players in the Needle-Free Injection System Market include companies such as Antares Pharma Inc., Endo International PLC, Inovio Pharmaceuticals Inc., Medical International Technology Inc., and others.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]